

## DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

CUPERTINO, Calif., Jan. 6, 2022 /PRNewswire/ — <u>DURECT Corporation</u> (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

Presentation details are as follows:

| H.C. Wainwright Bioconnect Conference |   |
|---------------------------------------|---|
| Date:                                 | January 10-13, 2022   |
| Time:                                 | On demand starting at 7:00 A.M. Eastern Standard Time               |
| Webcast:                              | https://journey.ct.eyents/view/bc235a31-51f3-4488-acfc-2334b2139c3e |

The webcast link of the presentation will also be available by accessing DURECT's homepage at <a href="www.www.durect.com">www.www.durect.com</a> and clicking on "Event Calendar" under the "Investors" section.

## **About DURECT Corporation**

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. Larsucosterol (also known as DUR-928), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for development and commercialization in the United States. Full prescribing information about POSIMIR, including the Boxed Warning, can be found at <a href="https://twitter.com/DURECTCorp">www.posimir.com</a>. For more information about DURECT, please visit <a href="https://twitter.com/DURECTCorp">www.www.durect.com</a> and follow us on Twitter <a href="https://twitter.com/DURECTCorp">https://twitter.com/DURECTCorp</a>.

**DURECT Forward-Looking Statement.** This press release contains forward-looking statements relating to, among other things, DURECT's relationship with Innocoll, statements about the potential launch of POSIMIR in the second quarter of 2022, statements about the potential for larsucosterol (also known as DUR-928) to treat patients with AH, NASH, multiple acute organ injury, chronic liver diseases and other diseases, ongoing clinical trials of larsucosterol, and the potential benefits of Fast Track Designation. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "planned," "will," "may," "expect," "anticipate," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on DURECT's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties that Innocoll may not launch POSIMIR as planned or commercialize POSIMIR successfully, if at all, the risk that the clinical trial of larsucosterol in AH takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that clinical trials of larsucosterol, including AHFIRM, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the lifesaving potential of larsucosterol in a statistically significant manner, the risk that Fast Track Designation for larsucosterol in AH may not lead to faster FDA review or an approval, risks related to DURECT's ability to obtain capital to fund operations and expenses, risks related to market competition, and other risks described in the "Risk Factors" section of DURECT's Quarterly Report on Form 10-Q for the period ended September 30, 2021 filed with the Securities and Exchange Commission (the " SEC") on November 3, 2021, and in other filings filed from time to time with the SEC. DURECT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER® is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective



owners. Larsucosterol (DUR-928) is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.



View original content:https://www.prnewswire.com/news-releases/durect-corporation-to-participate-in-hc-wainwright-

## bioconnect-conference-301455647.html

## **SOURCE DURECT Corporation**

Investor Relations (DURECT) – Michael Morabito, Ph. D., Solebury Trout, +1-646-378-2928, mmorabito@soleburytrout.com; or Media Contact (DURECT) – Mónica Rouco Molina, PhD, LifeSci Communications, +1-929-469-3850, mroucomolina@lifescicomms.com